title: PCSK9 inhibitors for hypercholesterolaemia.
authors.affiliation: William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, London, UK p.mcgettigan@qmul.ac.uk.
authors.forename: Patricia
authors.initials: P
authors.lastname: McGettigan
authors.affiliation: West Midlands Centre for Adverse Drug Reactions, City Hospital, Birmingham, UK.
authors.forename: Robin E
authors.initials: RE
authors.lastname: Ferner
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D008078:Cholesterol, LDL / Q000187:drug effects*; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D000091362:PCSK9 Inhibitors; D000071449:Proprotein Convertase 9
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D008078:Cholesterol, LDL; D000091362:PCSK9 Inhibitors; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9; C577155:evolocumab; C571059:alirocumab